Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Cancer supportive care products can be defined as products or drugs that are mainly used for treatment of adverse effects associated with cancer therapy as well as for treatment of symptoms and signs of cancer such nausea, vomiting, hair loss, low blood counts, and others.

Statistics:

The global cancer supportive care products market is estimated to account for US$ 40,884.0 Mn in terms of value by the end of 2027.

Global Cancer Supportive Care Products Market: Drivers

High prevalence of cancer is expected to propel growth of the global cancer supportive care products market over the forecast period. For instance, according to the American Cancer Society, in 2019, there will be an estimated 1,762,450 new cancer cases diagnosed and 606,880 cancer deaths in the U.S.

Moreover, increasing funding in cancer R&D is also expected to aid in growth of the global cancer supportive care products market. For instance, according to the National Cancer Research Institute (NCRI), cancer research funding by NCRI partners reached around US$ 750 million in 2018/19.

Statistics:

North America held dominant position in the global cancer supportive care products market in 2019, accounting for 43.6% share in terms of value, followed by Europe and Asia Pacific, respectively.

Figure 1: Global Cancer Supportive Care Products Market Share (%) Value, By Region, 2019

Cancer Supportive Care Products  | Coherent Market Insights

Global Cancer Supportive Care Products Market: Restraints

Loss of brands exclusivity of various generic drugs is expected to hinder growth of the global cancer supportive care products market.

Moreover, entry of biosimilars is also expected to limit growth of the global cancer supportive care products market. Patents for certain major drugs used in cancer supportive care products have expired or are expected to expire in the near future. This is projected to open the gateway for biosimilars for anti-cancer therapy, which would lead to drastic decrease in prices of patent-expired drugs.

request-sample

Cancer Supportive Care Products Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 27,244.1 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 4.6% 2027 Value Projection: US$ 40,884.0 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., France, Spain, Italy, Russia, Rest of Europe
  • Asia Pacific: China, Japan, India, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: North Africa, Central Africa, South Africa
Segments covered:
  • By Drug Class: Nonsteroidal Anti- Inflammatory Drugs, Anti-Infective, Anti-Emetics, Monoclonal Antibodies, Erythropoietin Stimulating Agents, Opioid Analgesics, Bisphosphonates, Granulocyte Colony Stimulating Factor.
  • By Indication: Lung Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Bladder Cancer, Leukemia, Ovary Cancer, Melanoma Cancer, Others.
  • By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Compounding Pharmacies.
Companies covered:

Amgen Inc., Johnson & Johnson Private Ltd., Merck, Novartis AG, Baxter International, Hoffmann-La Roche Ltd., Fagron, Teva Pharmaceutical Industries Ltd., G1 Therapeutics Inc., APR Applied Pharma Research s.a., Acacia Pharma, EMD Serono, and Kyowa Hakko Kirin Co., Ltd.

Growth Drivers:
  • Increasing prevalence of cancer
  • Approval and launch of new products
Restraints & Challenges:
  • Loss of brands exclusivity of various generic drugs

Global Cancer Supportive Care Products Market: Opportunities  

Increasing investment in the pharmaceutical sector is expected to offer lucrative growth opportunities for players in the global cancer supportive care products market. For instance, according to The European Federation of Pharmaceutical Industries and Associations’ Key Data 2019, the pharmaceutical sector in Europe invested US$ 19, 509 million in 2000, which increased to US$ 39,895 million (est.) in 2018. 

Moreover, R&D in cancer pain care is also expected to offer lucrative growth opportunities for players in the global cancer supportive care products market. For instance, in September 2020, EMD Serono presented its oncology portfolio and pipeline in supportive care in multiple cancers at ESMO 2020.

Statistics:

The global cancer supportive care products market was valued at US$ 27,244.1 Mn in 2019 and is forecast to reach a value of US$ 40,884.0 Mn by 2027 at a CAGR of 4.6% between 2020 and 2027.

Figure 2: Global Cancer Supportive Care Products Market Value (US$ Mn), 2016 – 2027

Cancer Supportive Care Products  | Coherent Market Insights

Market Trends/Key Takeaways

Use of targeted AML drugs alongside best supportive care may not be effective in improving quality of life in cancer patents. For instance, in August 2020, Bristol Myers Squibb reported that Idhifa, which bears an FDA nod in relapsed or refractory AML with an IDH2 mutation, failed to demonstrate efficacy in improving survival within that same patient population when used alongside best supportive care in a late-stage study.

Geriatric co-management for cancer patients is effective in cancer supportive care. For instance, according to a retrospective cohort study ‘Association of Geriatric Comanagement and 90-Day Postoperative Mortality Among Patients Aged 75 Years and Older With Cancer published in August 2020, in JAMA Network Open, geriatric co-management was associated with significantly lower 90-day postoperative mortality among older patients with cancer.

Regulations

Regulations (US) - Cancer Supportive Care

Approval Process

  • In the U.S., the FDA’s Oncologic Drugs Advisory Committee (ODAC) advises on each individual drug approval, meeting endpoint claims and labelling requirements
  • Approval regulations also are located under accelerated approval conditions for life- threatening conditions under section 21 CFR part 314, subpart H and 21 CFR part 601, subpart E of the U.S. FDCCA
  • The U.S. FDA recommends at least two adequate and well-controlled clinical trials for meeting endpoint of a critical drug
  • Various endpoints such as Disease-free-survival (DFS), Objective Response Rate (ORR), Time-to-Progression (TTP), Progression free survival, Time to treatment failure should be clearly mentioned during approval process of the drug and should be decided in co-ordication with the FDA

Off-label usage of drugs

  • Chemotherapy and other cancer-supportive drugs can be used off-label. It is primarily dependent on the stage of cancer and the disease progression rate
  • The best example for off-label drug usage in cancer supportive care is the pain medication through use of tricyclic anti-depressants
  • Another drugs used off-label in cancer supportive care is anti-nauseating drug ‘lorezepam’, administered mostly under the tongue (sub-lingual route). This is not a labelled administration route and the dosage and direction is fully dependent on physician
  • However, at certain times, lack of well-evidenced information on off-label drug usage leads to higher risk for medication errors, side effects, and unwanted drug reactions

Global Cancer Supportive Care Products Market: Competitive Landscape

Major players operating in the global cancer supportive care products market include, Amgen Inc., Johnson & Johnson Private Ltd., Merck, Novartis AG, Baxter International, Hoffmann-La Roche Ltd., Fagron, Teva Pharmaceutical Industries Ltd., G1 Therapeutics Inc., APR Applied Pharma Research s.a., Acacia Pharma, EMD Serono, and Kyowa Hakko Kirin Co., Ltd.

Global Cancer Supportive Care Products Market: Key Developments

Major players in the market are focused on presenting new portfolio in order to enhance their market share. For instance, in September 2020, Merck announced that more than 30 abstracts will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 from September 19-21. The abstracts span the company's clinical program in oncology across several innovative modalities and mechanisms that have the potential to advance treatment across a range of tumor types including biliary tract, lung and urothelial (bladder) cancers.

Cancer supportive care is associated with care given to the patients suffering from various types of cancer. Supportive care is intended for relieving suffering of the patients and improving their quality of life. The main aim of supportive care is to improve the quality of life of the patient. Cancer is one of the most prevalent fatal chronic disorders with a high mortality rate due to its invasive nature and prolonged duration of disease. High prevalence of cancer, increasing research and development along with increasing investment in biopharmaceutical industry are anticipated to drive the market growth during the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the Global Cancer Supportive Care Products market  and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the Global Cancer Supportive Care Products market  based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Amgen Inc., Johnson & Johnson Private Ltd., Merck, Novartis AG, Baxter International, Hoffmann-La Roche Ltd., Fagron, Teva Pharmaceutical Industries Ltd., G1 Therapeutics Inc., APR Applied Pharma Research s.a., Acacia Pharma, EMD Serono, and Kyowa Hakko Kirin Co., Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The Global Cancer Supportive Care Products market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Cancer Supportive Care Products market

Detailed Segmentation:

  • Global Cancer Supportive Care Products Market, By Drug Class:
    • Nonsteroidal Anti- Inflammatory Drugs
    • Anti-Infective
    • Anti-Emetics
    • Monoclonal Antibodies
    • Erythropoietin Stimulating Agents
    • Opioid Analgesics
    • Bisphosphonates
    • Granulocyte Colony Stimulating Factor
  • Global Cancer Supportive Care Products Market, By Indication:
    • Lung Cancer
    • Breast Cancer
    • Prostate Cancer
    • Liver Cancer
    • Bladder Cancer
    • Leukemia
    • Ovary Cancer
    • Melanoma Cancer
    • Others
  • Global Cancer Supportive Care Products Market, By Distribution Channel:
    • Hospital Pharmacies
    • Retail Pharmacies
    • Compounding Pharmacies
  • Global Cancer Supportive Care Products Market, By Region:
    • North America
      • By Drug Class:
        • Nonsteroidal Anti- Inflammatory Drugs
        • Anti-Infective
        • Anti-Emetics
        • Monoclonal Antibodies
        • Erythropoietin Stimulating Agents
        • Opioid Analgesics
        • Bisphosphonates
        • Granulocyte Colony Stimulating Factor
      • By Indication
        • Lung Cancer
        • Breast Cancer
        • Prostate Cancer
        • Liver Cancer
        • Bladder Cancer
        • Leukemia
        • Ovary Cancer
        • Melanoma Cancer
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Compounding Pharmacies
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Drug Class:
        • Nonsteroidal Anti- Inflammatory Drugs
        • Anti-Infective
        • Anti-Emetics
        • Monoclonal Antibodies
        • Erythropoietin Stimulating Agents
        • Opioid Analgesics
        • Bisphosphonates
        • Granulocyte Colony Stimulating Factor
      • By Indication
        • Lung Cancer
        • Breast Cancer
        • Prostate Cancer
        • Liver Cancer
        • Bladder Cancer
        • Leukemia
        • Ovary Cancer
        • Melanoma Cancer
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Compounding Pharmacies
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Drug Class:
        • Nonsteroidal Anti- Inflammatory Drugs
        • Anti-Infective
        • Anti-Emetics
        • Monoclonal Antibodies
        • Erythropoietin Stimulating Agents
        • Opioid Analgesics
        • Bisphosphonates
        • Granulocyte Colony Stimulating Factor
      • By Indication
        • Lung Cancer
        • Breast Cancer
        • Prostate Cancer
        • Liver Cancer
        • Bladder Cancer
        • Leukemia
        • Ovary Cancer
        • Melanoma Cancer
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Compounding Pharmacies
      • By Country
        • U.K.
        • Germany
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class:
        • Nonsteroidal Anti- Inflammatory Drugs
        • Anti-Infective
        • Anti-Emetics
        • Monoclonal Antibodies
        • Erythropoietin Stimulating Agents
        • Opioid Analgesics
        • Bisphosphonates
        • Granulocyte Colony Stimulating Factor
      • By Indication
        • Lung Cancer
        • Breast Cancer
        • Prostate Cancer
        • Liver Cancer
        • Bladder Cancer
        • Leukemia
        • Ovary Cancer
        • Melanoma Cancer
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Compounding Pharmacies
      • By Country
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Drug Class:
        • Nonsteroidal Anti- Inflammatory Drugs
        • Anti-Infective
        • Anti-Emetics
        • Monoclonal Antibodies
        • Erythropoietin Stimulating Agents
        • Opioid Analgesics
        • Bisphosphonates
        • Granulocyte Colony Stimulating Factor
      • By Indication
        • Lung Cancer
        • Breast Cancer
        • Prostate Cancer
        • Liver Cancer
        • Bladder Cancer
        • Leukemia
        • Ovary Cancer
        • Melanoma Cancer
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Compounding Pharmacies
      • By Country
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class:
        • Nonsteroidal Anti- Inflammatory Drugs
        • Anti-Infective
        • Anti-Emetics
        • Monoclonal Antibodies
        • Erythropoietin Stimulating Agents
        • Opioid Analgesics
        • Bisphosphonates
        • Granulocyte Colony Stimulating Factor
      • By Indication
        • Lung Cancer
        • Breast Cancer
        • Prostate Cancer
        • Liver Cancer
        • Bladder Cancer
        • Leukemia
        • Ovary Cancer
        • Melanoma Cancer
        • Others
      • By Distribution Channel
        • Hospital Pharmacies
        • Retail Pharmacies
        • Compounding Pharmacies
      • By Country
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
    • Amgen Inc.*
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Strategies
    • Johnson & Johnson Private Ltd.
    • Merck
    • Novartis AG
    • Baxter International
    • Hoffmann-La Roche Ltd.
    • Fagron
    • Teva Pharmaceutical Industries Ltd.
    • G1 Therapeutics Inc.
    • APR Applied Pharma Research S.A.
    • Acacia Pharma
    • EMD Serono
    • Kyowa Hakko Kirin Co., Ltd.
  •  “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Indication
      • Market Snippet, By Distribution Channel
      • Market Snippet, By Region
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Highlights
    • Product launch
    • PEST Analysis
    • Technological Advancements
    • Regulatory Scenario
    • Mergers and Acquisitions
  4. Global Cancer Supportive Care Products Market, By Drug Class, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Nonsteroidal Anti- Inflammatory Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Anti-Infective
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Anti-Emetics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Monoclonal Antibodies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Erythropoietin Stimulating Agents
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Opioid Analgesics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Bisphosphonates
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Granulocyte Colony Stimulating Factor
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  5. Global Cancer Supportive Care Products Market, By Indication, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Lung Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Breast Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Prostate Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Liver Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Bladder Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Leukemia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Ovary Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Melanoma Cancer
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Cancer Supportive Care Products Market, By Distribution CHannel, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospital Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Cancer Supportive Care Products Market, By Region, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Drug Class, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Indication, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Distribution Channel, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Company Profiles
      • Amgen Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Johnson & Johnson Private Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Merck
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Baxter International
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Hoffmann-La Roche Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Fagron
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Teva Pharmaceutical Industries Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • G1 Therapeutics Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • APR Applied Pharma Research S.A.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Acacia Pharma
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • FUJIFILM Medical Systems U.S.A.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • EMD Serono
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Kyowa Hakko Kirin Co., Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 28 market data tables and 20 figures on “Cancer Supportive Care Products Market - Global forecast to 2027”.

Frequently Asked Questions

The Global Cancer Supportive Care Products market size was valued at US$ 27,244.1 million in 2019 and is estimated to exhibit a CAGR of 4.6% between 2020 and 2027.
Erythropoietin Stimulating Agents segment held the major market share in 2019 owing to increasing prevalence of cancer and increasing product approvals is expected to propel growth of the market.
Major factor driving the growth of Global Cancer Supportive Care Products market during the forecast period increasing prevalence of cancer, increasing research & development , and adoption of expansion strategies from major companies.
Major factors hampering the growth of the Global Cancer Supportive Care Products market during the forecast period constitutes of Loss of brands exclusivity of various generic drugs.
North America market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Amgen Inc., Johnson & Johnson Private Ltd., Merck, Novartis AG, Baxter International, Hoffmann-La Roche Ltd., Fagron, Teva Pharmaceutical Industries Ltd., G1 Therapeutics Inc., APR Applied Pharma Research s.a., Acacia Pharma, EMD Serono, and Kyowa Hakko Kirin Co., Ltd.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner